Milk fermented with a 15-lipoxygenase-1-producing lactococcus lactis alleviates symptoms of colitis in a murine model

Current Pharmaceutical Biotechnology

Volumn 16, Issue 5, 2015, Pages 424-429

  Saraiva, Tessália D L ^a   Morais, Kátia ^a   Pereira, Vanessa B ^a   De Azevedo, Marcela ^a   Rocha, Clarissa S ^a   Prosperi, Camila C ^a   Gomes Santos, Ana C ^a   Bermudez Humaran, Luis ^b   Faria, Ana M C ^a   Blottiere, Hervé M ^b   Langella, Philippe ^b   Miyoshi, Anderson ^a   De De Leblanc, Alejandra Moreno ^c   Leblanc, Jean G ^c   Azevedo, Vasco ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UMR1319 MICALIS   (France)

^c CENTRO DE REFERENCIA PARA LACTOBACILOS CERELA CONICET   (Argentina)

Author keywords

Colitis; Fermented Milk; Inflammation; Lactic Acid Bacteria; Lactococcus Lactis Lipoxygenase

Indexed keywords

ARACHIDONATE 15 LIPOXYGENASE; TRINITROBENZENESULFONIC ACID; ALOX15 PROTEIN, HUMAN; ANTIINFLAMMATORY AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; DNA PURIFICATION; FERMENTATION; GENE EXPRESSION SYSTEM; INFLAMMATORY BOWEL DISEASE; INTESTINE INJURY; LACTIC ACID BACTERIUM; LACTOCOCCUS LACTIS; MILK PRODUCTION; MOUSE; MURINE MODEL; NONHUMAN; ULCERATIVE COLITIS; ANIMAL; BAGG ALBINO MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; ENZYMOLOGY; FEMALE; GENETICS; METABOLISM; MILK;

LACTOCOCCUS LACTIS; MURINAE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARACHIDONATE 15-LIPOXYGENASE; COLITIS; DISEASE MODELS, ANIMAL; FEMALE; FERMENTATION; LACTOCOCCUS LACTIS; MICE, INBRED BALB C; MILK; TRINITROBENZENESULFONIC ACID;

EID: 84929620686     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201015666141113123502     Document Type: Article

References (30)

1. [1] Maloy, K.J.; Powrie, F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature, 2011, 474(7351), 298-306.
2. [2] Dabritz, J. Granulocyte macrophage colony-stimulating factor and the intestinal innate immune cell homeostasis in Crohn's disease. Am. J. Physiol. Gastrointest. Liver Physiol., 2014, 306(6), G455-465.
3. [3] LeBlanc, J.G.; del Carmen, S.; Zurita T.M.; Alvarenga L.F.; Santos P.D.; Miyoshi, A.; Azevedo, V.; de Moreno de LeBlanc, A. Mechanisms involved in the anti-inflammatory properties of native and genetically engineered lactic acid bacteria. Anti-Infect. Agents, 2013, 11(1), 59-69.
4. [4] Bolotin, A.; Mauger, S.; Malarme, K.; Ehrlich, S.D.; Sorokin, A. Low-redundancy sequencing of the entire Lactococcus lactis IL1403 genome. A Van Leeuw J. Microb., 1999, 76(1-4), 27-76.
5. [5] Wells, J.M.; Mercenier, A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat. Rev. Micro-biol., 2008, 6(5), 349-362.
6. [6] del Carmen, S.; de Moreno de LeBlanc, A.; Perdigon, G.; Bastos Pereira, V.; Miyoshi, A.; Azevedo, V.; LeBlanc, J.G. Evaluation of the anti-inflammatory effect of milk fermented by a strain of IL-10-producing Lactococcus lactis using a murine model of Crohn's disease. J. Mol. Microbiol. Biotechnol., 2011, 21(3-4), 138-146.
7. [7] Lee, S.; Zuo, X.; Shureiqi, I. 15-Lipoxygenase-1 as a tumor sup- pressor gene in colon cancer: Is the verdict in? Cancer Metastasis Rev., 2011, 30(3-4), 481-491.
8. [8] Levy, B.D.; Clish, C.B.; Schmidt, B.; Gronert, K.; Serhan, C.N. Lipid mediator class switching during acute inflammation: Signals in resolution. Nat. Immunol., 2001, 2(7), 612-619.
9. [9] Serhan, C.N. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostagland. Leukotrien. Essential Fatty Acids, 2005, 73(3-4), 141-162.
10. [10] Godson, C.; Mitchell, S.; Harvey, K.; Petasis, N.A.; Hogg, N.; Brady, H.R. Cutting edge: Lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macro-phages. J. Immunol., 2000, 164(4), 1663-1667.
11. 11[] Jozsef, L.; Zouki, C.; Petasis, N.A.; Serhan, C.N.; Filep, J.G. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit per- oxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc. Natl. Acad. Sci. USA, 2002, 99(20), 13266-13271.
12. [12] Levy, B.D.; Fokin, V.V.; Clark, J.M.; Wakelam, M.J.; Petasis, N.A.; Serhan, C.N. Polyisoprenyl phosphate (PIPP) signaling regulates phospholipase D activity: A 'stop' signaling switch for aspirin-triggered lipoxin A4. FASEB J.: Offic. Public. Federat. Am. Soc. Experim. Biol., 1999, 13(8), 903-911.
13. [13] Aliberti, J. Host persistence: exploitation of anti-inflammatory pathways by Toxoplasma gondii. Nat. Rev. Immunol., 2005, 5(2), 162-170.
14. [14] Janakiram, N.B.; Rao, C.V. Role of lipoxins and resolvins as anti-inflammatory and proresolving mediators in colon cancer. Curr. Mol. Med., 2009, 9(5), 565-579.
15. [15] Miyoshi, A.; Jamet, E.; Commissaire, J.; Renault, P.; Langella, P.; Azevedo, V. A xylose-inducible expression system for Lactococcus lactis. FEMS Microbiol. Lett., 2004, 239(2), 205-212.
16. [16] del Carmen, S.; de Moreno de LeBlanc, A.; Martin, R.; Chain, F.; Langella, P.; Bermudez-Humaran, L.G.; LeBlanc, J.G. Genetically engineered immunomodulatory Streptococcus thermophilus strains producing antioxidant enzymes exhibit enhanced anti-inflammatory activities. Appl. Environ. Microbiol., 2014, 80(3), 869-877.
17. [17] Ameho, C.K.; Adjei, A.A.; Harrison, E.K.; Takeshita, K.; Morioka, T.; Arakaki, Y.; Ito, E.; Suzuki, I.; Kulkarni, A.D.; Kawajiri, A.; Yamamoto, S. Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis. Gut, 1997, 41(4), 487-493.
18. [18] Cenac, N.; Andrews, C.N.; Holzhausen, M.; Chapman, K.; Cottrell, G.; Andrade-Gordon, P.; Steinhoff, M.; Barbara, G.; Beck, P.; Bunnett, N.W.; Sharkey, K.A.; Ferraz, J.G.; Shaffer, E.; Vergnolle, N. Role for protease activity in visceral pain in irritable bowel syndrome. J. Clin. Invest., 2007, 117(3), 636-647.
19. [19] del Carmen, S.; Zurita-Turk, M.; Alvarenga, L.F.; Coelho dos Santos, J.S.; Leclercq, S.Y.; Chatel, J.-M.; Azevedo, V.; de Moreno de LeBlanc, A.; Miyoqhi, A.; LeBlanc, J.G. A novel Interleukin-10 DNA mucosal delivery system attenuates intestinal inflammation in a mouse model. Eur. J. Inflammat., 2013, 11(3), 641-655.
20. [20] Mangino, M.J.; Brounts, L.; Harms, B.; Heise, C. Lipoxin biosynthesis in inflammatory bowel disease. Prostagland. Other Lipid Mediators, 2006, 79(1-2), 84-92.
21. [21] Kim, J.S.; Baek, S.J.; Bottone, F.G.,; Sali, T.; Eling, T.E. Over-expression of 15-lipoxygenase-1 induces growth arrest through phosphorylation of p53 in human colorectal cancer cells. Mol. Cancer Res. MCR, 2005, 3(9), 511-517.
22. [22] Shureiqi, I.; Wojno, K.J.; Poore, J.A.; Reddy, R.G.; Moussalli, M.J.; Spindler, S.A.; Greenson, J.K.; Normolle, D.; Hasan, A.A.; Lawrence, T.S.; Brenner, D.E. Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers. Carcinogenesis, 1999, 20(10), 1985-1995.
23. [23] LeBlanc, J.G.; Aubry, C.; Cortes-Perez, N.G.; de Moreno de Le-Blanc, A.; Vergnolle, N.; Langella, P.; Azevedo, V.; Chatel, J.M.; Miyoshi, A.; Bermúdez-Humarán, L.G. Mucosal targeting of therapeutic molecules using genetically modified lactic acid bacteria: an update. FEMS Microbiol. Lett., 2013, 344(1), 1-9.
24. [24] LeBlanc, J.G.; de Moreno de LeBlanc, A.; Perdigón, G.; Miyoshi, A.; Rochat, T.; Bermudez-Humaran, L.; Langella, P.; Sesma, F.; Azevedo, V. Anti-inflammatory properties of lactic acid bacteria: Current knowledge, applications and prospects. Anti-Infect. Agents Medic. Chem., 2008, 7(3), 148-154.
25. [25] LeBlanc, J.G.; del Carmen, S.; Langella, P.; Bermudez-Humaran, L.; Alvarenga, L.F.; Zurita, T.M.; Santos, P.D.; Miyoshi, A.; Azevedo, V. Use of genetically engineered lactic acid bacteria for the treatment of Crohn’s Disease. In: Crohn’s Disease: Etiology, Diagnosis and Treatment Options; LeBlanc, J.G.; de Moreno de LeBlanc, A., Eds.; Nova Science Publishers, Inc.: Hauppauge, NY, USA, 2013, pp. 309-324.
26. [26] LeBlanc, J.G.; del Carmen, S.; Miyoshi, A.; Azevedo, V.; Sesma, F.; Langella, P.; Bermudez-Humaran, L.G.; Watterlot, L.; Perdi-gon, G.; de Moreno de LeBlanc, A. Use of superoxide dismutase and catalase producing lactic acid bacteria in TNBS induced Crohn's disease in mice. J. Biotechnol., 2011, 151(3), 287-293.
27. [27] Braat, H.; Rottiers, P.; Hommes, D.W.; Huyghebaert, N.; Remaut, E.; Remon, J.P.; van Deventer, S.J.; Neirynck, S.; Peppelenbosch, M.P.; Steidler, L. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin. Gastroenterol. Hepa-tol., 2006, 4(6), 754-759.
28. [28] Steidler, L.; Neirynck, S.; Huyghebaert, N.; Snoeck, V.; Vermeire, A.; Goddeeris, B.; Cox, E.; Remon, J.P.; Remaut, E. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat. Biotechnol., 2003, 21(7), 785-789.
29. [29] Diniz-Luerce, T.; Gomes-Santos, A.C.; Santos, R.C.; Moreira, T.G.; Cruz, D.N.; Lemos, L.; Sousa, A.L.; Bastos, P.V.; Azevedo, M.; Moraes, K.; Carmona, C.D.; LeBlanc, J.G.; Azevedo, V.; Caetano, F.A.M.; Miyoshi, A. Anti-inflammatory effects of Lacto-coccus lactis NCDO 2118 during the remission period of chemically-induced colitis. Gut Pathog., 2014, 6, 33.
30. [30] de Moreno de LeBlanc, A.; Chaves, S.; Perdigon, G. Effect of yoghhurt on the cytokine profile using a murine model of intestinal inflammation. Eur. J. Inflam., 2009, 7(2), 97-109.